IP Library › Granted Patent US 12,054,507
Granted Patent B2
US 12,054,507 · App. 17/178,156 · Granted Aug 6, 2024

Antiviral compounds

Inventors: Byoung-Kwon Chun (Pleasanton, CA); Edward Doerffler (Reno, NV); Dustin S. Siegel (Half Moon Bay, CA); Andrew C. Stevens (Edmonton, CA); Tiago Vieira (Edmonton, CA)
Assignee: GILEAD SCIENCES, INC.
C07F9/6561A61P31/14A61P31/16C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,507
App. No.
17/178,156
Granted
Aug 6, 2024
Kind
B2
Abstract

The present disclosure provides a compound of Formula I: which is useful in treating a variety of diseases, such as diseases caused by respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, HCV and/or HBV infections.

Claims (10)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical formulation comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

3. A method of treating a Pneumoviridae virus infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the Pneumoviridae virus infection is a respiratory syncytial virus infection.

4. A method of treating a Picornaviridae virus infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the Picornaviridae virus infection is human rhinovirus infection.

5. A method for the treatment or prophylaxis of an exacerbation of a respiratory condition by a viral infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the respiratory condition is chronic obstructive pulmonary disease, and wherein the infection is caused by a respiratory syncytial virus or rhinovirus.

6. A method for the treatment or prophylaxis of an exacerbation of a respiratory condition by a viral infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the respiratory condition is asthma, and wherein the infection is caused by respiratory syncytial virus or rhinovirus.

7. A compound having the structure:

8. A pharmaceutical composition comprising a compound having the structure:

and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: CHUN, BYOUNG-KWON; DOERFFLER, EDWARD; SIEGEL, DUSTIN S.; STEVENS, ANDREW C.; VIEIRA, TIAGO
To: GILEAD SCIENCES, INC.
Reel/Frame 056347/0458 →
Continuity (2)
Provisional Application 62977969 · Feb 18, 2020
Related Publication 20210284669A1 · Sep 16, 2021